Hepatocarcinoma cell-derived hepatoma-derived growth factor (HDGF) induces regulatory T cells

Cytokine

Volumn 72, Issue 1, 2015, Pages 31-35

  Sun, Ai Min ^a   Li, Chuan Gang ^a   Zhang, Yu Qin ^a   Lin, Shui Miao ^a   Niu, Hua Rui ^a   Shi, Yu Sheng ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

CD4 T cells; Foxp3; Hepatoma derived growth factor; Liver cancer; Regulatory T cells

Indexed keywords

BONE MORPHOGENETIC PROTEIN; CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CYTOKINE; HEPATOMA DERIVED GROWTH FACTOR; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; HEPATOMA-DERIVED GROWTH FACTOR; POLYINOSINIC POLYCYTIDYLIC ACID; SIGNAL PEPTIDE;

ANIMAL EXPERIMENT; ARTICLE; CANCER GROWTH; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; COCULTURE; CONTROLLED STUDY; CYTOTOXICITY; DILUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOCOMPETENT CELL; IMMUNOSURVEILLANCE; LIVER CELL CARCINOMA; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CYTOTOXIC T LYMPHOCYTE; IMMUNOLOGY; ISOLATION AND PURIFICATION; LIVER TUMOR; LYMPHOCYTE ACTIVATION; METABOLISM; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANIMALS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; COCULTURE TECHNIQUES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; POLY I-C; REAL-TIME POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY;

EID: 84920999763     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2014.12.001     Document Type: Article

References (28)

1. Flores A., Marrero J.A. Emerging trends in hepatocellular carcinoma: focus on diagnosis and therapeutics. Clin Med Insights Oncol 2014, 8:71-76.
2. Bertino G., Di Carlo I., Ardiri A., Calvagno G.S., Demma S., Malaguarnera G., et al. Systemic therapies in hepatocellular carcinoma: present and future. Future Oncol 2013, 9:1533-1548.
3. Giannelli G., Villa E., Lahn M. Transforming growth factor-beta as a therapeutic target in hepatocellular carcinoma. Cancer Res 2014, 74:1890-1894.
4. Kaech S.M., Hemby S., Kersh E., Ahmed R. Molecular and functional profiling of memory CD8 T cell differentiation. Cell 2002, 111:837-851.
5. Zhou H., Qiu J.H., Wang T., Yu Y.Y., Liu X.N., Li X., et al. Interleukin 27 inhibits cytotoxic T-lymphocyte-mediated platelet destruction in primary immune thrombocytopenia. Blood 2014, 124:3316-3319.
6. Liston A., Gray D.H. Homeostatic control of regulatory T cell diversity. Nat Rev Immunol 2014, 14:154-165.
7. Konkel J.E., Chen W. Balancing acts: the role of TGF-β in the mucosal immune system. Trends Mol Med 2011, 17:668-676.
8. Yang G., Geng X.-R., Song J.-P., Wu Y., Yan H., Zhan Z., et al. Insulin-like growth factor 2 enhances regulatory T-cell functions and suppresses food allergy in an experimental model. J Allergy Clin Immunol 2014, 133:1702-1708.
9. Terme M., Tartour E., Taieb J. VEGFA/VEGFR2-targeted therapies prevent the VEGFA-induced proliferation of regulatory T cells in cancer. Oncoimmunol 2013, 2:e25156.
10. Yang J., Everett A. Hepatoma derived growth factor binds DNA through the N-terminal PWWP domain. BMC Mol Biol 2007, 8:101.
11. Yang J., Everett A.D. Hepatoma-derived growth factor represses set and MYND domain containing 1 gene expression through interaction with C-terminal binding protein. J Mol Biol 2009, 386:938-950.
12. LaRue H., Ayari C., Bergeron A., Fradet Y. Toll-like receptors in urothelial cells-targets for cancer immunotherapy. Nat Rev Urol 2013, 10:537-545.
13. Seya T., Matsumoto M. The extrinsic RNA-sensing pathway for adjuvant immunotherapy of cancer. Cancer Immunol Immunother 2009, 58:1175-1184.
14. Everett A.D., Bushweller J. Hepatoma derived growth factor is a nuclear targeted mitogen. Curr Drug Target 2003, 4:367-371.
15. Kim G., Jang M.S., Son Y.M., Seo M.J., Ji S.Y., Han S.H., et al. Curcumin inhibits CD4(+) T cell activation, but augments CD69 expression and TGF-beta1-mediated generation of regulatory T cells at late phase. PloS One 2013, 8:e62300.
16. Smeltz R.B., Chen J., Shevach E.M. Transforming growth factor-beta1 enhances the interferon-gamma-dependent, interleukin-12-independent pathway of T helper 1 cell differentiation. Immunology 2005, 114:484-492.
17. Dardalhon V., Awasthi A., Kwon H., Galileos G., Gao W., Sobel R.A., et al. IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells. Nat Immunol 2008, 9:1347-1355.
18. Shih T.C., Tien Y.J., Wen C.J., Yeh T.S., Yu M.C., Huang C.H., et al. MicroRNA-214 downregulation contributes to tumor angiogenesis by inducing secretion of the hepatoma-derived growth factor in human hepatoma. J Hepatol 2012, 57:584-591.
19. Zhang J., Chen N., Qi J., Zhou B., Qiu X. HDGF and ADAM9 are novel molecular staging biomarkers, prognostic biomarkers and predictive biomarkers for adjuvant chemotherapy in surgically resected stage I non-small cell lung cancer. J Cancer Res Clin Oncol 2014, 140:1441-1449.
20. Wang L., Jiang Q., Hua S., Zhao M., Wu Q., Fu Q., et al. High nuclear expression of HDGF correlates with disease progression and poor prognosis in human endometrial carcinoma. Dis Marker 2014, 2014:298795.
21. Chen B., Huang T., Jiang J., Lv L., Li H., Xia S. MiR-141 suppresses proliferation and motility of gastric cancer cells by targeting HDGF. Mol Cel Biochem 2014, 388:211-218.
22. Li S.Z., Zhao Y.B., Cao W.D., Qu Y., Luo P., Zhen H.N., et al. The expression of hepatoma-derived growth factor in primary central nervous system lymphoma and its correlation with angiogenesis, proliferation and clinical outcome. Med Oncol 2013, 30:622.
23. Rutella S., Pierelli L., Bonanno G., Sica S., Ameglio F., Capoluongo E., et al. Role for granulocyte colony-stimulating factor in the generation of human T regulatory type 1 cells. Blood 2002, 100:2562-2571.
24. Collison L.W., Chaturvedi V., Henderson A.L., Giacomin P.R., Guy C., Bankoti J., et al. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol 2010, 11:1093-1101.
25. Kurachi M., Barnitz R.A., Yosef N., Odorizzi P.M., DiIorio M.A., Lemieux M.E., et al. The transcription factor BATF operates as an essential differentiation checkpoint in early effector CD8+ T cells. Nat Immunol 2014, 15:373-383.
26. Stephen T.L., Rutkowski M.R., Allegrezza M.J., Perales-Puchalt A., Tesone A.J., Svoronos N., et al. Transforming growth factor beta-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression. Immunity 2014, 41:427-439.
27. Takahashi Y., Mine J., Kubota Y., Yamazaki E., Fujiwara T. A substantial number of Rasmussen syndrome patients have increased IgG, CD4+ T cells, TNFα, and granzyme B in CSF. Epilepsia 2009, 50:1419-1431.
28. Wang B.-Q., Zhang C.-M., Gao W., Wang X.-F., Zhang H.-L., Yang P.-C. Cancer-derived matrix metalloproteinase-9 contributes to tumor tolerance. J Cancer Res Clin Oncol 2011, 137:1525-1533.